Trial Eligibility

* Complete radical mastectomy for feline mammary carcinoma
* No gross evidence of metastatic disease.

Trial Support

* Study sponsored by the University of Missouri in collaboration with the Veterinary Comparative Oncology Group. Study provides anthracycline chemotherapy.
* Costs associated with administration and follow up are not provided.

Thrombospondin-I antiangiogenic therapy for dogs with soft tissue sarcomas
Target Accrual= 60 cases
Status: Closed

Eligibility:

* Measurable, histologically confirmed soft tissue sarcomas not including hemangiosarcoma
* No chemotherapy within 14 days of trial entry
* No radiation therapy within 21 days of trial entry
* Prednisone or NSAID therapy permitted if introduced at least 2 weeks
* before trial entry
* No previous antiangiogenic therapy

Trial Support: Study patients receive thrombospondin-I peptide at no charge. The initial biopsy and sedation is covered by the study. Medical examinations and diagnostic tests needed to measure response are the responsibility of the owner. All cases must be evaluated and treated through a participating member of the Animal Clinical Investigations Network every 30 days following weekly visits during the first month. Diagnostic and staging tests may be performed at any veterinary hospital within 10 days of initiation of study. Gemcitabine chemotherapy available to dogs that fail the antiangiogenic phase of the study.